Eugene Demidenko

5PUBLICATIONS
31CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Pharmacology and pharmaceutical sciences not elsewhere classifiedContext learning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 08, 2025
Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.

Steven Tau, Mary D Chamberlin, Huijuan Yang

|Jul 13, 2023
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.

Nicole A Traphagen, Gary N Schwartz, Steven Tau

|Jun 01, 2023
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.

Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar

|Nov 26, 2019
Statistical determination of synergy based on Bliss definition of drugs independence.

Eugene Demidenko, Todd W Miller

|Aug 04, 2018
The next-generation K-means algorithm.

Eugene Demidenko

Pageof 1

Frequent Collaborators

3 joint publications

Jonathan D Marotti

3 joint publications

Shannon M Soucy

3 joint publications

Fred W Kolling

3 joint publications

Todd W Miller